A key FDA official told members of Congress last month that the agency supports the development of new drugs that contain cannabis or are derived from the plant.
Speaking before the House Committee on Energy and Commerce, Douglas Throckmorton, MD, deputy director for regulatory programs at the FDA’s Center for Drug Evaluation and Research, said investigators interested in conducting cannabis research that could lead to a drug approval need to first submit an investigational new drug (IND) application.
Voelker R. FDA Says It Supports Cannabis Drug Development via Regulatory Pathways. JAMA. 2020;323(7):600. doi:10.1001/jama.2020.0833
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: